Idorsia raises Sfr505m through share sale and CB to fund R&D
Idorsia, the Swiss biopharmaceutical company, has raised Sfr505m ($503.82m) to finance advanced clinical trials after a simultaneous share and convertible bond sale overnight in Zurich.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts